Saturday, October 17, 2015 1:55:50 PM
Bayer in liver indication still out there?
Partnering
Broad Networking for long-term success
To be able to develop innovative products, a company needs an appropriate environment – in Germany, in Europe and worldwide – and strong partners.
With a global network of external scientific and industrial development partners, we strengthen our own research infrastructure and, therefore, assure the long-term success of our product pipeline.
To supplement our internal efforts, we collaborate with several companies in different stages of the typical pharmaceutical research cycle. Our more significant collaborations are described (in alphabetical order) in the table below.
Partner
Objective
Affymetrix Understanding the disease mechanism and identifying new targets
ARTEMIS Pharmaceuticals GmbH In vivo validation of targets
Astra Zeneca Co-development of the selective estrogen receptor downregulator (SERD) for the treatment of hormonal dependent breast cancer
Avid Radiopharmaceuticals Radiopharmaceuticals compounds
Bausch&Lomb
SEGRA ophthalmology
Celera Genomic Cathepsin S inhibitor drug development program
ChemDiv Synthesis of compounds
ComGenex Synthesis of compounds
Genedata Expressionist software
Genzyme Corporation Campath in chronic lymphocytic leukemia and multiple sclerosis
Inpharmatica Kinase SARfari in Silico Drug Discovery
Johnson & Johnson Development of Rivaroxaban
Monash University New targets for gender health
MorphoSys AG Antibody diagnostics and therapeutics for cancer and other life threatening diseases
Nektar Therapeutics Targeted inhaled antibiotic therapy for pulmonary infections
Neurosciences Victoria Ltd. Treatment of neurodegenerative disorders
Novartis Pharma Research and development of inhibitors of angiogenesis
Nuvelo Development of alfimeprase
Onyx Co-development of Nexavar
Peregrine Pharmaceuticals, Inc. Selective cancer diagnostics (vascular targeting agents)
Philogen S.p.A. Development of immunoconjugates for cancer therapy and diagnosis
Proteros X-ray structure analysis
Regeneron Pharmaceuticals Development of the VEGF Trap for the treatment of eye diseases
Seattle Genetics Increasing the pool of potential drug candidates by biomolecules
Sonus Pharmaceuticals TOCOSOL Paclitaxel
Stanford University/Gambhir New PET tracers
Warner Chilcott SEGRA for dermatology
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM